Innoviva, Inc.(INVA): For the most recent quarter end, Innoviva, Inc. reported Annual Earnings of $0.25. Based on the filings, last years Annual Earnings was, $0.59. For the most recent quarter end, INVA reported a surprise Earnings per Share of 13.64% . The consensus estimate for current quarter is $0.27 and for the current fiscal year, the estimate is $1.09. For the Next fiscal year, the estimate is $1.37 based on the consensus.
Innoviva, Inc. has received $0.27 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $0.26 while the top line estimate is $0.27 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 278.57%. Innoviva, Inc. reported better than expected with a surprise EPS of 13.64% or $0.03 during its most recent quarterly earnings. The Actual EPS was $0.25 compared to the Estimated EPS of $0.22.
Innoviva Inc Last issued its quarterly earnings results on Feb 9, 2017. The company reported $0.22 EPS for the quarter. Analyst had a consensus estimate of $0.22. The company had revenue of $43.61 million for the quarter, compared to analysts expectations of $41.79 million. The companys revenue was up 90.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.04 EPS.
Company has reported several Insider transactions to the SEC, on Nov 22, 2016, Eric Desparbes (SVP and CFO) sold 1,800 shares at 10.89 per share price.On Nov 22, 2016, Theodore L Jr Witek (Sr. VP & Chief Scientific Off.) sold 3,700 shares at 10.84 per share price.On May 20, 2016, James L Tyree (director) sold 813 shares at 10.47 per share price.
Innoviva, Inc. (NASDAQ:INVA) witnessed a decline in the market cap on Wednesday as its shares dropped 1.1% or 0.13 points. After the session commenced at $11.76, the stock reached the higher end at $11.76 while it hit a low of $11.51. With the volume soaring to 881,408 shares, the last trade was called at $11.66. The company has a 52-week high of $14.15. The company has a market cap of $1,268 million and there are 108,731,402 shares in outstanding. The 52-week low of the share price is $8.67.
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The companys portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.